Organogenesis Holdings Inc Dossier - Source-backed chat

Organogenesis Holdings Inc

ORGONASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.22

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $1.40Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $180.1M

Enterprise Value $196.4M

Shares Outstanding 131.9M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Organogenesis is navigating severe headwinds due to changes in U.S. Medicare reimbursement policies for skin-substitute products, which caused a 58% year-over-year decline in Q1 2026 revenue. While the company has completed its rolling BLA submission for ReNu (targeting knee osteoarthritis) and is executing a 25% operating expense reduction program, near-term profitability remains highly pressured. A Hold recommendation is warranted until wound care sales stabilize and regulatory clarity on ReNu emerges.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$3.00

High · most bullish analyst$3.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5015%

Reimbursement pressures intensify, leading to further revenue declines below the guidance range, and the FDA issues a Complete Response Letter for ReNu, delaying commercialization.

Base CaseCentral scenario

$3.0060%

Matches the consensus mean

Organogenesis achieves its revised FY 2026 revenue guidance of $270M-$310M, successfully reduces operating expenses by 25%, and generates positive adjusted EBITDA in the second half of 2026 while ReNu remains under active FDA review.

Bull CaseUpside scenario

$6.0025%

Wound care market dynamics stabilize faster than expected, and the FDA approves ReNu in late 2026 or early 2027, unlocking a multi-billion dollar market in knee osteoarthritis.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Completed rolling BLA submission for ReNu in April 2026, targeting a large and growing knee osteoarthritis market.
Aggressive cost-restructuring plan targeting $14 million in annualized savings and a 25% reduction in FY 2026 operating expenses.
Strong balance sheet with $92.1 million in cash and no outstanding debt as of March 31, 2026.

Key Investment Risks

Extreme sensitivity to Medicare and CMS reimbursement policies for skin-substitute products.
Significant near-term revenue contraction (revised FY 2026 guidance implies a 45% to 52% annual decline).
Regulatory and clinical trial execution risks associated with the FDA approval process for ReNu.

Thesis Invalidation Triggers

Failure of the FDA to accept or approve the ReNu BLA.
Inability to achieve the targeted 25% operating expense reduction.
Further downward revisions to FY 2026 revenue guidance.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.